TargetMol

Ruzasvir

Product Code:
 
TAR-T68015
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T68015-1mg1mg£224.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68015-5mg5mg£456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68015-10mg10mg£622.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68015-25mg25mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68015-50mg50mg£1,259.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ruzasvir is a novel and potent pan-genotypic inhibitor of hepatitis C virus NS5A with antiviral activity.
CAS:
1613081-64-3
Molecular Weight:
947.09
Pathway:
Microbiology/Virology|Proteases/Proteasome
Purity:
0.9701
SMILES:
FC1=C2C=3N([C@@H](OC2=CC(=C1)C=4NC(=NC4)[C@H]5N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC5)C=6SC(=NC6)C7CC7)C=8C(C3)=CC(=CC8)C=9NC(=NC9)[C@H]%10N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC%10
Target:
HCV Protease

References

Asante-Appiah E, et al. In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01280-18. Wyles D, et al. C-CREST Part C and C-SURGE Investigators. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 Dec;66(6):1794-1804.